Antibiotic

Global Animal Growth Promoters and Performance Enhancers Market Analytics and Opportunity Outlook 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 15, 2021
Agriculture, Health, Natural Resources, Veterinary, Acidifier, Population, Hormone, Climate change, Livestock, Adoption, Industry, Government, USD, CAGR, Egg, Growth, Poultry, Probiotic, Animal, Product-service system, Prebiotic (nutrition), Antibiotic, Epidemic, Feed manufacturing, Agriculture

Growth in the animal growth promoters and performance enhancers market is majorly driven by the rising demand for animal consumption and consumption of livestock-based products, rising global demand for naturally produced growth promoters, and rising animal epidemics and climate change.

Key Points: 
  • Growth in the animal growth promoters and performance enhancers market is majorly driven by the rising demand for animal consumption and consumption of livestock-based products, rising global demand for naturally produced growth promoters, and rising animal epidemics and climate change.
  • The non-antibiotic growth promoters and performance enhancers segment accounted for the largest share of the animal growth promoters and performance enhancers market in 2020.
  • Based on animal type, the poultry segment accounted for the largest share of the global animal growth promoters and performance enhancers market.
  • It aims at estimating the market size and future growth potential of the global animal growth promoters and performance enhancers market and different segments such as type, animal type and region.

Palette Life Sciences Celebrates Twenty Years of Deflux Treatment for Vesicoureteral Reflux (VUR) in the United States

Retrieved on: 
Tuesday, November 9, 2021
Urine, Antibiotic prophylaxis, Kidney, Pediatric urology, Urology, Caregiver, Education, VUR, Recurrence, CEO, Disease, Hyaluronic acid, Professor, FAAP, Sugar, UTI, Emory University School of Medicine, Goal, Urinary tract infection, Research, PMID, Radiation, FDA, Board, Incidence, AAP, GLOBE, Polysaccharide, Reflux nephropathy, Physician, Globe, Antibiotic, Palette, Patient, Pharmaceutical industry, Wine, Animal, Medicine

SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, Inc., a fully integrated life sciences company dedicated to improving patient outcomes, today announced the 20th anniversary of Deflux in the United States, the only FDA-approved minimally invasive, highly effective treatment for vesicoureteral reflux (VUR).

Key Points: 
  • SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, Inc. , a fully integrated life sciences company dedicated to improving patient outcomes, today announced the 20th anniversary of Deflux in the United States , the only FDA-approved minimally invasive, highly effective treatment for vesicoureteral reflux (VUR).
  • Deflux has been widely used as a minimally invasive treatment for VUR ever since, providing a highly effective, non-surgical treatment alternative to long-term antibiotics.
  • Deflux was available through Nestl Skin Health until 2018, when Palette Life Sciences entered into an agreement with Nestl Skin Health to license worldwide commercialization and development rights for Deflux.
  • Intermediate to long-term follow-up indicates low risk of recurrence after double hit endoscopic treatment for primary vesicoureteral reflux.

What can $2.1 billion do for infection control in the wake of COVID-19?

Retrieved on: 
Monday, September 20, 2021
White House, Federal Government, Public Policy, Government, Healthcare Reform, Health, Public Policy, General Health, Infection, Compliance, Interview, Solution, IPC, White House, Lawyer, Student, Patient, NHSN, Dialysis, LinkedIn, Hospital, Centers for Disease Control and Prevention, CDC, Nursing, Public health, Center, CIC, MPH, White, Risk, COVID-19, Research, Learning, Data collection, Antibiotic, WKL, Pharmaceutical industry, Medicine

What: The Center for Disease Control and Prevention (CDC) announced on Friday that the agency will be investing $2.1 billion to improve infection prevention and control activities across the U.S. public health and healthcare sectors.

Key Points: 
  • What: The Center for Disease Control and Prevention (CDC) announced on Friday that the agency will be investing $2.1 billion to improve infection prevention and control activities across the U.S. public health and healthcare sectors.
  • Why: The investment will allow the United States to improve public health and the quality of healthcare, including addressing healthcare-related inequities.
  • The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide.
  • For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth .

SAS and bioMérieux join forces to fight antimicrobial resistance

Retrieved on: 
Monday, August 9, 2021
Technology, Software, Infection, CLARION, Data management, Disease, Health, COVID-19, Bacteria, AMR, Center, SAS Institute Inc v World Programming Ltd, HIMSS, Intelligence, Centers for Disease Control and Prevention, Name, EMR, Death, Antibiotic, SAS, Partnership, Anecdote, Public health, Antimicrobial stewardship, Risk, Data collection, Doctor of Pharmacy, Patient, Data visualization, POWER, Fungus, National Health Laboratory Service, Hospital, Pharmaceutical industry, Medical imaging, Satellite navigation device

CARY, N.C., Aug. 9, 2021 /PRNewswire/ -- bioMrieux Inc. , a world leader in in vitro diagnostic solutions for infectious disease, has partnered with global analytics leader SAS to help combat antimicrobial resistance.

Key Points: 
  • CARY, N.C., Aug. 9, 2021 /PRNewswire/ -- bioMrieux Inc. , a world leader in in vitro diagnostic solutions for infectious disease, has partnered with global analytics leader SAS to help combat antimicrobial resistance.
  • The partnership is rooted in the medical community's ongoing fight against antimicrobial resistance and the goal to activate and support continuous improvement within antimicrobial stewardship programs.
  • "CLARION, powered by SAS, revolutionizes antimicrobial stewardship and transforms the antibiogram to be automated and dynamic, providing up-to-date information."
  • SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries.

Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145

Retrieved on: 
Wednesday, July 28, 2021
Health, Science, Pharmaceutical, Research, Clinical trials, Chemical compounds, Organic compounds, Heterocyclic compounds, Beta-lactamase, Antibiotic, Beta-lactamase inhibitors, β-Lactamase inhibitor, Pharmacokinetics, Cefepime, VNRX-7145, Venatorx Pharmaceuticals, Inc., VNRX-7145, VENATORX PHARMACEUTICALS, INC.

Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial ( ClinicalTrials.gov NCT04243863 ) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.

Key Points: 
  • Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial ( ClinicalTrials.gov NCT04243863 ) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.
  • The Phase 1 study was a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics (PK) of escalating oral doses of VNRX-7145.
  • Venatorxs two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam/beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively.
  • In addition, Venatorx is in Phase 1 with its first antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor.

Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update

Retrieved on: 
Wednesday, July 28, 2021
Health, Medical specialties, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Antibiotic, Fidaxomicin

It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.

Key Points: 
  • It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
  • The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com .

Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam

Retrieved on: 
Tuesday, July 27, 2021
Health, Articles, Moraxellaceae, Carbapenem, Healthcare-associated infections, Acinetobacter, Antimicrobial resistance, Antibiotic, ESKAPE

WALTHAM, Mass. and SHANGHAI, China and SAN FRANCISCO, July 27, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, and Zai Lab Limited (NASDAQ:ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, announced today that patient enrollment in the ATTACK Phase 3 registrational clinical trial of sulbactam-durlobactam (SUL-DUR) is now complete, with top-line data readout anticipated early in the fourth quarter of 2021.

Key Points: 
  • To our knowledge, ATTACK is the largest antibiotic-resistant, pathogen-specific registrational trial to be conducted globally and the first to focus specifically on carbapenem-resistant Acinetobacter infections.
  • Harald Reinhart, M.D., Chief Medical Officer for Autoimmune and Infectious Diseases at Zai Lab, stated, Infections caused by carbapenem-resistant Acinetobacter spp.
  • ATTACK is a Phase 3 registrational trial that will evaluate the safety and efficacy of SUL-DUR in patients with confirmed carbapenem-resistant Acinetobacter infections.
  • ATTACK is a global Phase 3 registration trial that enrolled patients at clinical sites from 17 countries.

Recce Pharmaceuticals Announces Anti-Viral Patent Granted in USA for RECCE® Anti-Infectives

Retrieved on: 
Thursday, July 22, 2021
Epidemiology, Infectious diseases, Health sciences, Health, Medicine, Recce, Antibiotic, Antiviral drug, Virus, South African Special Forces, Infection, Pathogen

We are thrilled to see that our Anti-viral patent granted in the USA, the largest pharmaceutical market in the world; with yet further market-monopolies reinforcing the unique opportunities among a significant range of both bacterial and viral pathogens.

Key Points: 
  • We are thrilled to see that our Anti-viral patent granted in the USA, the largest pharmaceutical market in the world; with yet further market-monopolies reinforcing the unique opportunities among a significant range of both bacterial and viral pathogens.
  • The U.S. pharma industry has shouldered the responsibility of developing and manufacturing some of the worlds most innovative and best-selling drugs.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Recce Pharmaceuticals Announces Anti-Viral Patent Granted in China for RECCE® Anti-Infectives

Retrieved on: 
Wednesday, July 21, 2021
Health sciences, Health, Epidemiology, Infectious diseases, Medicine, Recce, Pharmaceutical industry, Antibiotic, Virus, South African Special Forces, Infection, Patent

With this new patent granted in one of the largest pharmaceutical markets in the world, our market-monopolies reinforce the unique opportunities among a significant range of both bacterial and viral pathogens.

Key Points: 
  • With this new patent granted in one of the largest pharmaceutical markets in the world, our market-monopolies reinforce the unique opportunities among a significant range of both bacterial and viral pathogens.
  • This is the third Patent in Family 3 to be granted to the Company following its recent patent grant in Europe and Japan, with applications among other major pharmaceutical markets around the world in their advanced stages of independent patent reviews.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

A new avenue for fighting drug-resistant bacteria

Retrieved on: 
Thursday, July 15, 2021
Branches of biology, Health sciences, Biology, Bacteriology, Bacterial diseases, RNA, Microbiology, Infectious diseases, Antimicrobial resistance, Antibiotic, Bacteria, RNA interference

Professor Charles Dozois from Institut national de la recherche scientifique (INRS) and doctoral student Hicham Bessaiah see a promising avenue for more effective treatment of antibiotic-resistant bacteria.

Key Points: 
  • Professor Charles Dozois from Institut national de la recherche scientifique (INRS) and doctoral student Hicham Bessaiah see a promising avenue for more effective treatment of antibiotic-resistant bacteria.
  • The bacteria have to withstand the environmental stressors in order to cause a bladder infection.
  • "Without the regulatory RNA, the bacteria is more sensitive to changes in the environment and loses its infectious capacity," explained the doctoral student.
  • The regulatory RNA sequence studied by the researchers is also found in a number of other major pathogenic bacteria.